Cogstate Ltd · ASX:CGS
Cogstate — Healthcare & Biotechnology Event (March 2010)
12 slides from Cogstate's conference presentation, Mar 24, 2010
Slide 1: Healthcare & Biotechnology Event
For personal use only Healthcare & Biotechnology Event 24 March 2010 www.cogstate.com
Slide 2: Company overview
Company overview CogState Ltd (ASX:CGS) For personal use only • a profitable health services, technology company that provides cognition-testing software to pharmaceutical companies undertaking clinical trials • Cognition testing is used in many clinical trials for drugs designed to work on central
Slide 3: Financial summary
Financial summary Share price $0.29 Major Shareholders Shares Held (%) For personal use only Market cap $19.2 m Martyn Myer 11,000,000 16.58% GBS Venture Management Pty Ltd 7,470,868 11.26% Cash (as at 28/02/10) $ 3.3 m Asia Union Investments Pty Ltd 6,423,619 9.68% 52 week high $0.38 Citicorp Nomin
Slide 4: Expanding market
Expanding market • There has been a structural migration towards computerised For personal use only testing • Advantages of computerised testing: – Culture neutral stimuli, meaning anyone can be tested regardless of language, literacy, ethnicity and socio-economic status – Allows for non-expert admi
Slide 5: The CogState advantage
The CogState advantage • Validity of tests For personal use only – Confirmed in over 150 peer-reviewed scientific articles • Extensive commercial experience in study design – CogState experts have published over 300 journal articles, co-authored numerous book chapters, and edited and authored textbo
Slide 6: Revenue is increasing
For personal use only Revenue is increasing • Sales contracts are predominantly charged in US $ • Despite the strong Australian dollar CogState’s revenue has grown significantly www.cogstate.com
Slide 7: Increase value of sales contracts
For personal use only Increase value of sales contracts Almost 100% growth on previous corresponding period www.cogstate.com
Slide 8: Contracted future revenue on the rise
Contracted future revenue on the rise • Contracted future revenue is secured by a signed sales For personal use only contract and will be recognised as revenue upon achievement of a milestone at a future point in time • Currently, $4.4 million of contracted future revenue – up from $3.3m million at
Slide 9: Alzheimer's Disease opportunity
Alzheimer’s Disease opportunity • Alzheimer’s Disease (AD) clinical trials require cognition For personal use only endpoints for regulatory approval • CogState is a licensed distributor of the Neuropsychological Test Battery (NTB) – An increasingly important test fully validated and accepted by the
Slide 10: Is the growth sustainable?
Is the growth sustainable? • Increased use of CogState in phase 2 and 3 clinical trials For personal use only – Larger contracts over longer time period, providing greater certainty of contracted revenue from future periods • Cognition continues to be an area of focus in many indications, but partic
Slide 11: In summary
In summary • Financially profitable and cash flow positive business For personal use only – Profitable results recorded for the last three consecutive half years – Cash holdings $3.3 million, up from $2.5 million at 31 Dec 2009 • Fast growing – revenue grew by 122% in FY09 and 61% in FY08 – Sales co
Slide 12: Brad O'Connor, Chief Executive Officer
For personal use only Brad O’Connor Chief Executive Officer CogState Ph: 03 9664 1300 boconnor@cogstate.com www.cogstate.com
Cogstate — Healthcare & Biotechnology Event (March 2010) on 6ix